Trifunctional Triomab® Antibodies for Cancer Therapy

Lindhofer, Horst; Hess, Juergen; Ruf, Peter

doi:10.1007/978-3-642-20910-9_16

Horst Lindhofer^2,3,
Juergen Hess² &
Peter Ruf³

2456 Accesses
7 Citations

Abstract

In the 1980s, two groups described in parallel and for the first time T-cell-redirecting bispecific antibodies (bsAbs) for the elimination of tumor cells (Perez et al. 1985; Staerz et al. "CR60">1985). In vitro, this approach was extremely potent, highlighting the superiority of T-cell-induced compared to accessory cell-mediated killing. But two major drawbacks hampered the rapid transition of this new approach from preclinical investigations to successful clinical trials and market approval.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Chapter: USD 29.95; Price excludes VAT (USA)

eBook: USD 169.00; Price excludes VAT (USA)

Softcover Book: USD 219.99; Price excludes VAT (USA)

Hardcover Book: USD 219.99; Price excludes VAT (USA)

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

Boruchov AM, Heller G, Veri MC, Bonvini E, Ravetch JV, Young JW (2005) Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J Clin Invest 115:2914–2923
Article PubMed CAS Google Scholar
Buhmann R, Simoes B, Stanglmaier M, Yang T, Faltin M, Bund D, Lindhofer H, Kolb HJ (2009) Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 × anti-CD20 antibody and donor lymphocyte infusion. Bone Marrow Transplant 43:383–397
Article PubMed CAS Google Scholar
Burges A, Wimberger P, Kümper C, Gorbounova V, Sommer H, Schmalfeldt B, Pfisterer J, Lichinitser M, Makhson A, Moiseyenko V, Lahr A, Schulze E, Jäger M, Ströhlein MA, Heiss MM, Gottwald T, Lindhofer H, Kimmig R (2007) Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM × anti-CD3 antibody: a phase I/II study. Clin Cancer Res 13(13):3899–3905
Article PubMed CAS Google Scholar
Burton DR (1985) Immunoglobulin G: functional sites. Mol Immunol 22:161–206
Article PubMed CAS Google Scholar
Cartron G, Watier H, Golay J, Solal-Celigny P (2004) From the bench to the bedside: ways to improve rituximab efficacy. Blood 104(9):2635–2642
Article PubMed CAS Google Scholar
Chames P, Baty D (2009) Bispecific antibodies for cancer therapy. Curr Opin Drug Discov Devel 12(2):276–283
PubMed CAS Google Scholar
Chassoux DM, Linares-Cruz LG, Bazin H, Stanislawski M (1988) K-cell-mediated cytotoxicity induced with rat monoclonal antibodies. I. Antibodies of various isotypes differ in their ability to induce cytotoxicity mediated by rat and human effectors. Immunology 65:623–628
PubMed CAS Google Scholar
Chelius D, Ruf P, Gruber P, Ploscher M, Liedtke R, Gansberger E, Hess J, Wasiliu M, Lindhofer H (2010) Structural and functional characterization of the trifunctional antibody catumaxomab. MAbs 2(3):309–319
Article PubMed Google Scholar
Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6:443–446
Article PubMed CAS Google Scholar
Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10(9):942–949
Article PubMed CAS Google Scholar
De Lau WB, Heije K, Neefjes JJ, Oosterwegel M, Rozemuller E, Bast BJ (1991) Absence of preferential homologous H/L chain association in hybrid hybridomas. J Immunol 146:906–914
PubMed Google Scholar
de Souza AP, Bonorino C (2009) Tumor immunosuppressive environment: effects on tumor-specific and nontumor antigen immune responses. Expert Rev Anticancer Ther 9(9):1317–1332
Article PubMed Google Scholar
Deisenhofer J (1981) Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution. Biochemistry 20:2361–2370
Article PubMed CAS Google Scholar
Del Prete G, de Carli M, Almerigogna F, Giudizi MG, Biagiotti R, Romagnani S (1993) Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. J Immunol 150:353–360
PubMed Google Scholar
Desjarlais JR, Lazar GA, Zhukovsky EA, Chu SY (2007) Optimizing engagement of the immune system by anti-tumor antibodies: an engineer’s perspective. Drug Discov Today 12:898–910
Article PubMed CAS Google Scholar
Dhodapkar KM, Banerjee D, Connolly J, Kukreja A, Matayeva E, Veri MC, Ravetch JV, Steinman RM, Dhodapkar MV (2007) Selective blockade of the inhibitory Fcgamma receptor (FcgammaRIIB) in human dendritic cells and monocytes induces a type I interferon response program. J Exp Med 204:1359–1369
Article PubMed CAS Google Scholar
Grigg A, Ritchie D (2004) Graft-versus-lymphoma effects: clinical review, policy proposals, and immunobiology. Biol Blood Marrow Transplant 10(9):579–590
Article PubMed CAS Google Scholar
Gronau SS, Schmitt M, Thess B, Reinhardt P, Wiesneth M, Schmitt A, Riechelmann H (2005) Trifunctional bispecific antibody-induced tumor cell lysis of squamous cell carcinomas of the upper aerodigestive tract. Head Neck 27:376–382
Article PubMed Google Scholar
Haagen IA, Geerars AJ, Clark MR, van de Winkel JG (1995) Interaction of human monocyte Fc gamma receptors with rat IgG2b. A new indicator for the Fc gamma RIIa (R-H131) polymorphism. J Immunol 154:1852–1860
PubMed CAS Google Scholar
Heiss MM, Strohlein MA, Jager M, Kimmig R, Burges A, Schoberth A, Jauch KW, Schildberg FW, Lindhofer H (2005) Immunotherapy of malignant ascites with trifunctional antibodies. Int J Cancer 117:435–443
Article PubMed CAS Google Scholar
Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, Dudnichenko AS, Aleknaviciene B, Razbadauskas A, Gore M, Ganea-Motan E, Ciuleanu T, Wimberger P, Schmittel A, Schmalfeldt B, Burges A, Bokemeyer C, Lindhofer H, Lahr A, Parsons SL (2010) The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer 27(9):2209–2221
Article Google Scholar
Hirschhaeuser F, Leidig T, Rodday B, Lindemann C, Mueller-Klieser W (2009) Test system for trifunctional antibodies in 3D MCTS culture. J Biomol Screen 14:980–990
Article PubMed CAS Google Scholar
Jacobs N, Mazzoni A, Mezzanzanica D, Negri DR, Valota O, Colnaghi MI, Moutschen MP, Boniver J, Canevari S (1997) Efficiency of T cell triggering by anti-CD3 monoclonal antibodies (mAb) with potential usefulness in bispecific mAb generation. Cancer Immunol Immunother 44:257–264
Article PubMed CAS Google Scholar
Jäger M, Schoberth A, Theissen B, Hess J, Friccius-Quecke H, Lindhofer H (2009a) Decrease of VEGF within malignant ascites during catumaxomab treatment: results from a pivotal phase II/III study. J Clin Oncol 27:15s (suppl; abstr 3029)
Article Google Scholar
Jäger M, Schoberth A, Ruf P, Hess J, Lindhofer H (2009b) The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor 2. Cancer Res 69:4270–4276
Article PubMed Google Scholar
Jäger M, Schoberth A, Hennig M, Burges A, Heiss M, Wimberger P, Schmalfeldt B, Lindhofer H (2010) The trifunctional antibody catumaxomab (anti-EpCAM × anti-CD3) in patients with malignant ascites: immunomonitoring results of a pivotal phase II/III study (pooled population). J Clin Oncol 28:15s, suppl; abstr 2521)
Google Scholar
Jung G, Freimann U, Von Marschall Z, Reisfeld RA, Wilmanns W (1991) Target cell-induced T cell activation with bi- and trispecific antibody fragments. Eur J Immunol 21(10):2431–2435
Article PubMed CAS Google Scholar
Kalergis AM, Ravetch JV (2002) Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells. J Exp Med 195:1653–1659
Article PubMed CAS Google Scholar
Kiewe P, Hasmuller S, Kahlert S, Heinrigs M, Rack B, Marme A, Korfel A, Jager M, Lindhofer H, Sommer H, Thiel E, Untch M (2006) Phase I trial of the trifunctional anti-HER2 × anti-CD3 antibody ertumaxomab in metastatic breast cancer. Clin Cancer Res 12:3085–3091
Article PubMed CAS Google Scholar
Koolwijk P, van de Winkel JG, Pfefferkorn LC, Jacobs CW, Otten I, Spierenburg GT, Bast BJ (1991) Induction of intracellular Ca²⁺ mobilization and cytotoxicity by hybrid mouse monoclonal antibodies. Fc gamma RII regulation of Fc gamma RI-triggered functions or signaling? J Immunol 147:595–602
PubMed CAS Google Scholar
Larson LN, Johansson C, Lindholm L, Holmgren J (1988) Mouse monoclonal antibodies for experimental immunotherapy promotes killing of tumor cells. Int J Cancer 42:877–882
Article PubMed CAS Google Scholar
Lindhofer H, Mocikat R, Steipe B, Thierfelder S (1995) Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. J Immunol 155:219–225
PubMed CAS Google Scholar
Lindhofer H, Schobert A, Pelster D, Hess J, Herold J, Jäger M (2009) Elimination of cancer stem cells (CD133+/EpCAM+) from malignant ascites by the trifunctional antibody catumaxomab: results from a pivotal trial. J Clin Oncol 27:15s (suppl; abst 3014)
Article Google Scholar
Linke R, Klein A, Seimetz D (2010) Catumaxomab: clinical development and future directions. MAbs 2(2):129–136
Article PubMed Google Scholar
Milstein C, Cuello AC (1983) Hybrid hybridomas and their use in immunohistochemistry. Nature 305:537–540
Article PubMed CAS Google Scholar
Moore GL, Chen H, Karki S, Lazar GA (2010) Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions. MAbs 2(2):181–189
Article PubMed Google Scholar
Morecki S, Lindhofer H, Yacovlev E, Gelfand Y, Slavin S (2006) Use of trifunctional bispecific antibodies to prevent graft versus host disease induced by allogeneic lymphocytes. Blood 107(4):1564–1569
Article PubMed CAS Google Scholar
Morecki S, Lindhofer H, Yacovlev E, Gelfand Y, Ruf P, Slavin S (2008) Induction of long-lasting antitumor immunity by concomitant cell therapy with allogeneic lymphocytes and trifunctional bispecific antibody. Exp Hematol 36(8):997–1003
Article PubMed CAS Google Scholar
Müller D, Kontermann RE (2010) Bispecific antibodies for cancer immunotherapy. BioDrugs 24(2):89–98
Article PubMed Google Scholar
Onishi H, Wada J, Suzuki H, Yamasaki A, Nagai S, Morisaki T, Katano M (2010) Effect of TGF-β1 expressed on tumor-derived exosomes on survival and function of regulatory T cells. J Clin Oncol 28:15s (suppl; abstr 2567)
Google Scholar
Ott MG, Lindhofer H, Linke RG, Hennig M, Martinius H, Klein A, Seimetz D (2010) The trifunctional antibody catumaxomab: correlation between immunological response and clinical outcome – new analysis of a pivotal phase II/III study. J Clin Oncol 28:15s (suppl; abstr 2551)
Google Scholar
Parsons SL, Lang MW, Steele RJ (1996) Malignant ascites: a 2-year review from a teaching hospital. Eur J Surg Oncol 22:237–239
Article PubMed CAS Google Scholar
Perez P, Hoffman RW, Shaw S, Bluestone JA, Segal DM (1985) Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody. Nature 316:354–356
Article PubMed CAS Google Scholar
Porakishvili N, Kardava L, Jewell AP, Yong K, Glennie MJ, Akbar A, Lydyard PM (2004) Cytotoxic CD4+ T cells in patients with B cell chronic lymphocytic leukemia kill via a perforin-mediated pathway. Haematologica 89(4):435–443
PubMed CAS Google Scholar
Porter DL, Levine BL, Bunin N, Stadtmauer EA, Luger SM, Goldstein S, Loren A, Phillips J, Nasta S, Perl A, Schuster S, Tsai D, Sohal A, Veloso E, Emerson S, June CH (2006) A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood 107(4):1325–1331
Article PubMed CAS Google Scholar
Racila E, Link BK, Weng WK, Witzig TE, Ansell S, Maurer MJ, Huang J, Dahle C, Halwani A, Levy R, Weiner GJ (2008) A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clin Cancer Res 14:6697–6703
Article PubMed CAS Google Scholar
Renner C, Held G, Ohnesorge S, Bauer S, Gerlach K, Pfitzenmeier JP, Pfreundschuh M (1997) Role of naive and memory T cells in tumor cell lysis mediated by bi-specific antibodies. Immunobiology 197:122–132
Article PubMed CAS Google Scholar
Richards JO, Karki S, Lazar GA, Chen H, Dang W, Desjarlais JR (2008) Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells. Mol Cancer Ther 7:2517–2527
Article PubMed CAS Google Scholar
Riechelmann H, Wiesneth M, Schauwecker P, Reinhardt P, Gronau S, Schmitt A, Schroen C, Atz J, Schmitt M (2007) Adoptive therapy of head and neck squamous cell carcinoma with antibody coated immune cells: a pilot clinical trial. Cancer Immunol Immunother 56:1397–1406
Article PubMed CAS Google Scholar
Riesenberg R, Buchner A, Pohla H, Lindhofer H (2001) Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM × alpha CD3). J Histochem Cytochem 49:911–917
Article PubMed CAS Google Scholar
Robb RJ, Munck A, Smith KA (1981) T cell growth factor receptors. Quantitation, specificity, and biological relevance. J Exp Med 154:1455–1474
Article PubMed CAS Google Scholar
Ruf P, Lindhofer H (2001) Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood 98:2526–2534
Article PubMed CAS Google Scholar
Ruf P, Jager M, Ellwart J, Wosch S, Kusterer E, Lindhofer H (2004) Two new trifunctional antibodies for the therapy of human malignant melanoma. Int J Cancer 108:725–732
Article PubMed CAS Google Scholar
Ruf P, Kluge M, Jäger M, Burges A, Volovat C, Heiss MM, Hess J, Wimberger P, Brandt B, Lindhofer H (2010) Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients. Br J Clin Pharmacol 69(6):617–625
Article PubMed CAS Google Scholar
Sebastian M, Passlick B, Friccius-Quecke H, Jager M, Lindhofer H, Kanniess F, Wiewrodt R, Thiel E, Buhl R, Schmittel A (2007) Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM × anti-CD3): a phase I study. Cancer Immunol Immunother 56:1637–1644
Article PubMed CAS Google Scholar
Sebastian M, Kiewe P, Schuette W, Brust D, Peschel C, Schneller F, Ruhle KH, Nilius G, Ewert R, Lodziewski S, Passlick B, Sienel W, Wiewrodt R, Jager M, Lindhofer H, Friccius-Quecke H, Schmittel A (2009a) Treatment of malignant pleural effusion with the trifunctional antibody catumaxomab (Removab) (anti-EpCAM × Anti-CD3): results of a phase 1/2 study. J Immunother 32:195–202
Article PubMed CAS Google Scholar
Sebastian M, Kuemmel A, Schmidt M, Schmittel A (2009b) Catumaxomab: a bispecific trifunctional antibody. Drugs Today 45(8):589–597
Article PubMed CAS Google Scholar
Shen J, Zhu Z (2008) Catumaxomab, a rat/murine hybrid trifunctional bispecific monoclonal antibody for the treatment of cancer. Curr Opin Mol Ther 10(3):273–284
PubMed CAS Google Scholar
Smith W, Jarrett AL, Beattie RE, Corvalan JR (1992) Immunoglobulins secreted by a hybrid-hybridoma: analysis of chain assemblies. Hybridoma 11:87–98
Article PubMed CAS Google Scholar
Staerz UD, Kanagawa O, Bevan MJ (1985) Hybrid antibodies can target sites for attack by T cells. Nature 314:628–631
Article PubMed CAS Google Scholar
Stanglmaier M, Faltin M, Ruf P, Bodenhausen A, Schroder P, Lindhofer H (2008) Bi20 (FBTA05), a novel trifunctional bispecific antibody (anti-CD20 × anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels. Int J Cancer 123:1181–1189
Article PubMed CAS Google Scholar
Stemmler HJ, Salat C, Lindhofer H, Menzel H, Untch M, Kahlert S, Konecny G, Sauer H, Ledderose G, Heinemann V, Kolb HJ (2005) Combined treatment of metastatic breast cancer (MBC) by high-dose chemotherapy (HDCT) and bispecific antibodies: a pilot study. Anticancer Res 25:3047–3054
PubMed CAS Google Scholar
Ströhlein MA, Heiss MM (2009) Intraperitoneal immunotherapy to prevent peritoneal carcinomatosis in patients with advanced gastrointestinal malignancies. J Surg Oncol 100(4):329–330
Article PubMed Google Scholar
Ströhlein MA, Siegel R, Jäger M, Lindhofer H, Jauch KW, Heiss MM (2009) Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis. J Exp Clin Cancer Res 28:18
Article PubMed Google Scholar
Tiebout RF, van Boxtel-Oosterhof F, Stricker EA, Zeijlemaker WP (1987) A human hybrid hybridoma. J Immunol 139:3402–3405
PubMed CAS Google Scholar
Walz A, Mack B, Schmitt B, Gires O, Wollenberg B, Zeidler R (2004) Antitumour effects of a bispecific trivalent antibody in multicellular tumour spheroids. Anticancer Res 24:887–893
PubMed CAS Google Scholar
Weiner GJ, Kostelny SA, Hillstrom JR, Cole MS, Link BK, Wang SL, Tso JY (1994) The role of T cell activation in anti-CD3 × antitumor bispecific antibody therapy. J Immunol 152:2385–2392
PubMed CAS Google Scholar
Weng WK, Levy R (2003) Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21:3940–3947
Article PubMed CAS Google Scholar
Zeidler R, Reisbach G, Wollenberg B, Lang S, Chaubal S, Schmitt B, Lindhofer H (1999) Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J Immunol 163:1246–1252
PubMed CAS Google Scholar
Zeidler R, Mysliwietz J, Csanady M, Walz A, Ziegler I, Schmitt B, Wollenberg B, Lindhofer H (2000) The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer 83:261–266
Article PubMed CAS Google Scholar

Download references

Author information

Authors and Affiliations

TRION Pharma GmbH, Frankfurter Ring 193a, 80807, Munich, Germany
Horst Lindhofer & Juergen Hess
TRION Research GmbH, Am Klopferspitz 19, 82152, Martinsried, Germany
Horst Lindhofer & Peter Ruf

Authors

Horst Lindhofer
View author publications
You can also search for this author in PubMed Google Scholar
Juergen Hess
View author publications
You can also search for this author in PubMed Google Scholar
Peter Ruf
View author publications
You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Horst Lindhofer .

Editor information

Editors and Affiliations

Inst. Zellbiologie und Immunologie, Universität Stuttgart, Allmandring 31, Stuttgart, 70569, Germany
Roland E. Kontermann

Rights and permissions

Reprints and permissions

Copyright information

About this chapter

Cite this chapter

Lindhofer, H., Hess, J., Ruf, P. (2011). Trifunctional Triomab^® Antibodies for Cancer Therapy. In: Kontermann, R. (eds) Bispecific Antibodies. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-20910-9_16

Download citation

DOI: https://doi.org/10.1007/978-3-642-20910-9_16
Published: 01 July 2011
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-20909-3
Online ISBN: 978-3-642-20910-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)

Publish with us

Policies and ethics